A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
Stopped early · Phase 1/Phase 2
Conditions studied: Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC), Squamous Cell Carcinoma of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Bladder Cancer, Uterine Cancer
In brief
The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
Key facts
- Study ID
- NCT04424641
- Run by
- Genmab
- People needed
- 48
- Starts
- 2020-07-15
- Expected to finish
- 2021-10-29
- Last updated by the study team
- 2023-07-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Tennesse Oncology, PLLC - Nashville — Nashville, Tennessee, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Rigshospitalet (Copenhagen University Hospital) — Copenhagen, Denmark
- Chaim Sheba Medical Center — Ramat Gan, Israel
- Hospital Universitari Vall d'Hebron — Barcelona, Spain
- Fundacion Jimenez Diaz — Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.